Compare Roopa Industries with Similar Stocks
Dashboard
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 8.82%
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.82 times
With a growth in Operating Profit of 56.65%, the company declared Very Positive results in Mar 26
With ROCE of 15.6, it has a Very Attractive valuation with a 1.5 Enterprise value to Capital Employed
Majority shareholders : Non Institution
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
INR 41 Cr (Micro Cap)
10.00
33
0.00%
1.68
23.69%
2.35
Total Returns (Price + Dividend) 
Roopa Industries for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Are Roopa Industries Ltd latest results good or bad?
Roopa Industries Ltd's latest financial results for Q4 FY26 present a complex picture. The company reported a net loss of ₹1.43 crores, a significant shift from a profit of ₹0.77 crores in the previous quarter (Q3 FY26). This marks a notable decline in net profitability, raising concerns about the sustainability of its growth trajectory. On the revenue front, Roopa Industries generated ₹30.14 crores in Q4 FY26, reflecting a sequential decline of 10.14% from ₹33.54 crores in Q3 FY26, although it achieved a modest year-on-year growth of 1.04% compared to ₹29.83 crores in Q4 FY25. This sequential revenue drop may indicate normal quarterly volatility rather than a fundamental weakening in demand. Despite the challenges at the net profit level, the company demonstrated operational improvements, achieving an operating margin of 10.19%, the highest in eight quarters. This represents a substantial enhancement fro...
Read full news article
Roopa Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness
Roopa Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a significant shift in its valuation parameters, moving from an attractive to a very attractive rating. This change comes despite mixed returns relative to the broader market and peers, signalling a potential opportunity for investors seeking value in a challenging industry environment.
Read full news article
Roopa Industries Q4 FY26: Loss-Making Quarter Raises Red Flags Despite Revenue Gains
Roopa Industries Ltd., a micro-cap pharmaceutical bulk drug manufacturer with a market capitalisation of ₹41.00 crores, reported a concerning loss of ₹1.43 crores in Q4 FY26, marking a sharp reversal from the ₹0.77 crores profit recorded in the previous quarter. The Adoni-based company, which trades at ₹52.90 on the exchanges, saw its stock gain 2.66% in the trading session following the results announcement, though the counter remains down 21.07% over the past year.
Read full news article Announcements 
Submission Of Audited Financial Results For The Quarter And Year Ended 31/03/2026
30-May-2026 | Source : BSESubmission of Audited Financial Results for the quarter and year ended 31/03/2026
Announcement under Regulation 30 (LODR)-Change in Management
30-May-2026 | Source : BSERe-appointment of Cost Auditor for FY 2026-27
Board Meeting Outcome for Outcome Of Board Meeting
30-May-2026 | Source : BSEOutcome of Board Meeting
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 1 FIIs (0.25%)
Star Niochem Pvt Limited (18.91%)
Sangeetha S (9.51%)
41.0%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is -10.14% vs 16.70% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is -285.71% vs 67.39% in Dec 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 6.15% vs 106.60% in Sep 2024
Growth in half year ended Sep 2025 is -12.79% vs 7.50% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 7.17% vs 87.94% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -6.17% vs 51.40% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 5.64% vs 71.36% in Mar 2025
YoY Growth in year ended Mar 2026 is -96.06% vs 33.55% in Mar 2025






